EYPT
EyePoint Pharmaceuticals, Inc.
There isn't enough reported data to score EYPT yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
EYPT Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Unavailable |
EYPT's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
EYPT PE Valuation
EYPT has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
EYPT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Moderate | |
| Low |
Analysts expect EYPT's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
EYPT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.97 | -$0.97 |
| Q2 2026 | -$3.75 | -$1.06 |
| Q1 2026 | -$3.51 | -$1.09 |
| Q4 2025 | -$3.17 | -$0.85 |
| Q3 2025 | -$3.00 | -$1.01 |
| Q2 2025 | -$2.69 | -$0.91 |
| Q1 2025 | -$2.42 | -$0.61 |
| Q4 2024 | -$2.32 | -$0.50 |
EYPT is still losing money, but less than at its worst: $3.97 per share over the past year, against $5.60 at its worst in late 2019.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over EYPT on earnings quality, reporting a profit while its opponent remains loss making.
EYPT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $756K | -22% |
| Q2 2026 | $507K | -90% |
| Q1 2026 | $696K | -97% |
| Q4 2025 | $620K | -95% |
| Q3 2025 | $966K | -91% |
| Q2 2025 | $5.3M | -44% |
| Q1 2025 | $24.5M | +109% |
| Q4 2024 | $11.6M | -17% |
EYPT's revenue has slid since its 2025 peak: $756,000 last quarter, down 22% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -12814% | -6394 points |
| Q2 2026 | -19207% | -18040 points |
| Q1 2026 | -12532% | -12333 points |
| Q4 2025 | -11346% | -10956 points |
| Q3 2025 | -6421% | -6110 points |
| Q2 2025 | -1167% | -802 points |
| Q1 2025 | -200% | +86 points |
| Q4 2024 | -390% | -274 points |
EYPT's operating margin was −12814% last quarter, down 6394 points from the same quarter a year ago, near the bottom of its range since 2019.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over EYPT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over EYPT on profitability, with a higher operating margin.
EYPT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$88M | -$27.9M |
| Q2 2026 | -$63.5M | +$261K |
| Q1 2026 | -$81.5M | -$28.2M |
| Q4 2025 | -$66M | -$29.8M |
| Q3 2025 | -$60.2M | -$19.6M |
| Q2 2025 | -$63.8M | -$42.7M |
| Q1 2025 | -$53.4M | -$21M |
| Q4 2024 | -$36.2M | -$12.2M |
EYPT has burned cash in almost every quarter: −$299M over the past year, against −$214M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over EYPT on cash generation, producing positive trailing cash flow while its opponent burns cash.
EYPT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +28% | +15.3M shares |
| 1 year | +86% | +32.2M shares |
| 3 years | +143% | +41M shares |
EYPT has 70M diluted shares, up 86% from a year ago.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over EYPT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
EYPT Net Leverage
EYPT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
EYPT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 22.9 | Oversold |
| Stochastic | 0.1 | Oversold |
EYPT's weekly RSI is 23 (oversold) and its Stochastic is 0 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
EYPT PE vs Healthcare Sector
EYPT has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
EYPT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.84 | 83% below |
| 20 week MA | $6.61 | 95% below |
| 50 week MA | $11.3 | 97% below |
| 100 week MA | $10.3 | 97% below |
| 200 week MA | $10.8 | 97% below |
EYPT is in a downtrend: it's below all five of its weekly moving averages, and 97% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over EYPT on trend strength, trading above more of its moving averages.
EYPT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $15.0 | $4.99 | -67% |
| 2021 | $4.99 | $13.6 | +172% |
| 2022 | $13.6 | $2.89 | -79% |
| 2023 | $2.89 | $23.1 | +700% |
| 2024 | $23.1 | $7.20 | -69% |
| 2025 | $7.20 | $18.3 | +154% |
| 2026 YTD | $18.3 | $0.32 | -98% |
EYPT's yearly returns have swung widely, from +700% in 2023 to −79% in 2022. It's down 98% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over EYPT on returns for 2026, with the stronger performance.